Key Account Management Europe Summit

eyeforpharma29 - 30 November 2010, London, UK.
eyeforpharma's Key Account Management Europe Summit, taking place in London in November, includes a half-day workshop led by David Wright, director of Imonic, a leading expert on KAM and chair of the KAM stream at SFE Europe 2010 in Barcelona. Following the success of the SFE event, which attracted over 200 delegates to the KAM element alone, David's detailed discussions with Kate Eversole and eyeforpharma contributed to the formulation of the new London-based KAM summit, which we are delighted to see includes an impressive program of speakers from both pharma and healthcare providers.

The November workshop will focus on providing practical solutions, and will address in particular the following:

  • How to get and keep commitment from your leadership team, not just a token lip-service acceptance (e.g., comments such as "You can implement KAM but you can't change the organizational structure or the incentive scheme, and we're not investing in new IT systems!"). How do you prove that the ‘old model' is broken and no longer works? How do you exploit and communicate the benefits of KAM and get the investments and commitments you need to make a success of KAM in your organization?
  • How to measure KAM effectively. The temptation is to still track 'calls per day', but the emphasis with KAM is on quality, not quantity, so other metrics become relevant. What are these metrics? How do they correlate to sales and how can they be implemented?
  • Why is effective planning critical to the success of KAM? How do you get the balance right between time allocated to planning and time in the field? What constitutes best practice as far as planning is concerned, and how can effective account strategies be developed and implemented?
  • How to align IT systems to support best practice in KAM and how to develop a clear statement of requirements and assess the gaps.
  • What are the account management skills critical for KAM success? How do we achieve a high quality of engagement from account teams?
  • How to use a customer feedback program to improve success with KAM and identify what customers want and evaluate their feedback.

Imonic's David Wright will offer unique insights into how pharma should confront these challenges in 2011, with practical advice and solutions based on Imonic's experiences of KAM implementation in pharma and for over 20 years in other sectors.

For further information and registration, please visit:
http://www.eyeforpharma.com/kameu/

About eyeforpharma
eyeforpharma is a division of a private company headquartered in London, UK. We have offices in New York, South Africa and Australia. We have grown by at least 30% per year since our creation in 2002.

We are the sum of the quality of those people and pride ourselves on recruiting not only the professional and innovative but the personable. That is why so many of our contacts are now our friends aswell as our trusted advisors. It is this level of dialogue that we seek to promote throughout the pharma world.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...